Nabriva Therapeutics AG (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $9.25 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 12.53% from the company’s current price.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

NBRV has been the topic of a number of other research reports. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research report on Friday, September 1st. SunTrust Banks, Inc. started coverage on Nabriva Therapeutics AG in a research report on Friday, August 25th. They set a “buy” rating and a $20.00 price target on the stock. ValuEngine raised Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price target (up previously from $15.00) on shares of Nabriva Therapeutics AG in a research report on Tuesday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target (up previously from $16.00) on shares of Nabriva Therapeutics AG in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $18.78.

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) opened at 8.22 on Wednesday. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $14.10. The company has a 50-day moving average price of $8.44 and a 200 day moving average price of $9.84. The firm’s market cap is $220.61 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million. Analysts expect that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.

WARNING: “Nabriva Therapeutics AG (NBRV) Upgraded to “Buy” by Zacks Investment Research” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/11/nabriva-therapeutics-ag-nbrv-upgraded-to-buy-by-zacks-investment-research.html.

In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 57,175 shares of the firm’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $10.53, for a total value of $602,052.75. Following the sale, the insider now owns 2,565,661 shares of the company’s stock, valued at approximately $27,016,410.33. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of Nabriva Therapeutics AG stock in a transaction on Monday, September 18th. The stock was acquired at an average cost of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 57,219 shares of company stock worth $535,919 and sold 252,845 shares worth $2,585,694. Company insiders own 2.75% of the company’s stock.

Several hedge funds have recently modified their holdings of NBRV. Wellington Management Group LLP boosted its holdings in shares of Nabriva Therapeutics AG by 9.9% in the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after purchasing an additional 193,951 shares in the last quarter. Almanack Investment Partners LLC. acquired a new stake in shares of Nabriva Therapeutics AG in the 1st quarter valued at $1,870,000. Nationwide Fund Advisors boosted its holdings in shares of Nabriva Therapeutics AG by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares in the last quarter. 50.23% of the stock is currently owned by hedge funds and other institutional investors.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.